Sona Presents Additional Preclinical Data Demonstrating Repeated Ability Of Its Cancer Therapy To Inhibit Tumor Growth In Colorectal Cancer Model

Stock Information for BioVaxys Technology Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About BioVaxys Technology Corp.

Sona Nanotech Reports 80% Response Rate in First-In-Human THT Cancer Therapy Study
Sona Nanotech To Host Investor Webinar To Discuss Clinical Study
Sona Provides Update on First-In-Human Clinical Trial
Sona Announces Canadian Melanoma Clinical 'Pilot' Study Ethics Approval
First Patient Dosed in Early Feasibility Study Trial of its Cancer Therapy
Sona Announces Ethics Committee Approval For Melanoma Clinical Trial
Sona Engages Clinical Trial Clinic for First-in-Human Early Feasibility Study of its THT Cancer Therapy
Sona Successfully Completes FDA-Required Toxicity Study

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.